

## List of references NT-219

### **NT157/NT219 - Main publications**

1. Reuveni H\*, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, and Levitzki A\*. Therapeutic destruction of insulin receptor substrates for cancer treatment. *Cancer research*. 2013 Jul 15;73(14):4383-94.  
<https://cancerres.aacrjournals.org/content/canres/73/14/4383.full.pdf>
2. Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME, Levitzki A, and Cox ME\*. The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer. *Mol Cancer Ther*. 2014; 13(12): 2827-2839.  
<https://mct.aacrjournals.org/content/13/12/2827.full-text.pdf>
3. Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, M Karin M\*. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. *Oncogene* 2016; 35:2634–44.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791217/pdf/nihms712222.pdf>
4. Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y, Bar-Eli M, Reuveni H\* and Levitzki A\*. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. *Oncogene* 2016; 35:2675–80.  
<https://doi.org/10.1038/onc.2015.229>
5. Rampias T, Favicchio R, Stebbing J, Giamas G. Targeting tumor–stroma crosstalk: the example of the NT157 inhibitor. *Oncogene* 2016; 35(20):2562-4.  
<https://doi.org/10.1038/onc.2015.392>
6. Machado-Neto JA, Fenerich BA, Rodrigues Alves APN, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, and Traina F\*. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. *Clinics* 2018, 73(Suppl. 1), e566s.  
<https://doi.org/10.6061/clinics/2018/e566s>

### **STAT3 in Cancer & Drug Resistance**

1. Zou, S., Tong, Q., Liu, B. *et al.* Targeting STAT3 in Cancer Immunotherapy. *Mol Cancer* 2020; **19**, 145.  
<https://doi.org/10.1186/s12943-020-01258-7>
2. Ho-June Lee, Guanglei Zhuang, Yi Cao, Pan Du, Hyo-Jin Kim, and Jeff Settleman. Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. *Cancer Cell* 2014; 26: 207–221.  
[https://www.cell.com/cancer-cell/pdfExtended/S1535-6108\(14\)00225-6](https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(14)00225-6)
3. Chengguang Zhao, Huameng Li, Huey-Jen Lin, Shulin Yang, JiayuhLin, and GuangLiang. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. *Trends in pharmacological sciences* 2016; 37(1): P47-61.  
<https://doi.org/10.1016/j.tips.2015.10.001>

### **IRS1/2 Roles in Cancer & Drug Resistance**

1. Jacob Berger, A., Gigi, E., Kupersmidt, L. *et al.* IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. *Nat Cancer* 2, 1055–1070 (2021). <https://doi.org/10.1038/s43018-021-00261-1>
2. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. *Cell Commun Signal*. 2009; 7:14.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709114/pdf/1478-811X-7-14.pdf>

3. Simpson, A., Petnga, W., Macaulay, V.M. et al. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. *Targ Oncol* 12, 571–597 (2017)  
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610669/pdf/11523\\_2017\\_Article\\_514.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610669/pdf/11523_2017_Article_514.pdf)